A perfect storm: Root cause analysis of supra-therapeutic anticoagulation with vitamin K antagonists during the COVID-19 pandemic
Authors:
- 1 August 2020
- journal article
- letter
- Published by Elsevier in Thrombosis Research
- Vol. 192, 73-74
Abstract
No abstract availableKeywords
Funding Information
- Sanofi
- Pfizer
- Bayer
This publication has 6 references indexed in Scilit:
- Liver injury in COVID-19: management and challengesThe Lancet Gastroenterology & Hepatology, 2020
- Mitigating and learning from the impact of COVID‐19 infection on addictive disordersAddiction, 2020
- Adherence to long‐term anticoagulation treatment, what is known and what the future might holdBritish Journal of Haematology, 2016
- Definition of clinically relevant non‐major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non‐surgical patients: communication from the SSC of the ISTHJournal of Thrombosis and Haemostasis, 2015
- Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patientsJournal of Thrombosis and Haemostasis, 2005
- Acetaminophen and Other Risk Factors for Excessive Warfarin AnticoagulationJAMA, 1998